The current clinical management of abdominal aortic aneurysm (AAA) disease is based to a great extent on measuring the aneurysm maximum diameter to decide when timely intervention is required. Decades of clinical evidence show that aneurysm diameter is positively associated with the probability of rupture, but that other parameters may also play a role in causing or predisposing the AAA to rupture. Biological factors associated with smooth muscle apoptosis are implicated in AAA expansion while geometric and biomechanical factors identified by means of computational modeling techniques have been positively correlated with rupture risk with a higher accuracy and sensitivity than maximum diameter alone. The objective of this review is to examine the factors found to influence AAA disease progression, clinical management and rupture, as well as a patent review that highlights developments in this arena in the past few years.
Keywords: Abdominal aortic aneurysm, biological factor of AAA growth, biomechanical factors of AAA rupture, geometric factors of AAA rupture risk, intraluminal thrombus (ILT), tissue inhibitors of metalloproteinases (TIMP), wall stress.
Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach
Current Vascular Pharmacology Problems and Perspectives of Abdominal Aortic Aneurysm Research
Current Drug Targets Segmentation of Blood Vessel Structures in Retinal Fundus Images with Logarithmic Gabor Filters
Current Medical Imaging Molecular Genetics of Abdominal Aortic Aneurysm: Therapeutic Implications
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A Systematic Review of the Literature
Current Vascular Pharmacology Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Screening Aortic Drug Treatments Through Arterial Compliance Measurements
Current Vascular Pharmacology Gender Differences in Types, Frequency, Clinical Manifestations and Atherosclerotic Burden of Coronary Artery Anomalies
Reviews on Recent Clinical Trials Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures
Current Drug Targets Role of Contrast-Enhanced Ultrasound in the Follow-up of Endo-Vascular Aortic Aneurysm Repair: an Effective and Safe Surveillance Method
Current Pharmaceutical Design Intraventricular Recombinant Tissue Plasminogen Activator in Treatment of Aneurysmal Intraventricular Hemorrhage: A Meta-Analysis
Current Drug Targets Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design